Improving Treatments - Improving Lives

Based in Hørsholm, Denmark, with an office in New York, LifeCycle Pharma (LCP) is an emerging specialty pharmaceutical company. Clinical development is the core of LCP’s effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP’s unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability – at low scale-up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide®, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP).

Recent News

Aug 27, 2010
LifeCycle Pharma announces Shionogi Pharma terminates Fenoglide® North American commercialization agreement

Aug 18, 2010
LifeCycle Pharma announces result for the first half 2010 in line with expectations

Aug 13, 2010
Investor Service Announcement no. 3/2010: LifeCycle Pharma A/S to Host Conference Call on Wednesday August 18, 2010

Archive »